The pharmacokinetics and pharmacodynamics of desmopressin: Effect on plasma factor VIII:C and von Willebrand Factor

American Journal of Therapeutics

Volumn 4, Issue 1, 1997, Pages 3-8

  Argenti, Domenick ^a,b   Jensen, Bradford K ^a   Heald, Donald ^a  

^a SANOFI   (France)

^b US Prescription Products Division   (United States)

Author keywords

desmopressin; hemophilia A; pharmacodynamic pharmacokinetic model; von Willebrand disease

Indexed keywords

BLOOD CLOTTING FACTOR 8C; DESMOPRESSIN; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD CHEMISTRY; DRUG EFFECT; HEMOPHILIA A; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN DETERMINATION;

EID: 0030947896     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199701000-00002     Document Type: Article

References (16)

1. Robinson AG: DDAVP in the treatment of central diabetes. N Engl J Med 1976;294:507-511.
2. Birkasova M, Birkas O, Flynn MJ, Cort JH: Desmopressin in the management of nocturnal enuresis in children: a double-blind study. Pediatrics 1978;62:970-974.
3. Hilton P, Stanton SL: The use of desmopressin in nocturnal urinary frequency in the female. Br J Urol 1982; 54:252-255.
4. Rosa RM, Bierer BE, Thomas R, et al.: A study of induced hyponatremia in the prevention and treatment of sickle-cell crisis. N Engl J Med 1980;303:1138-1143.
5. Mannucci PM, Canciani MT, Rota L, Donovan BS: Response of factor VIII/von Willebrand's factor to desmopressin in healthy subjects and patients with haemophilia A and von Willebrand's disease. Br J Haematol 1981;47:283-293.
6. 2-type vasopressin activity: findings and implications. Mol Cell Endocrinol 1989;64:133-136.
7. Hashemi S, Tackaberry ES, Palmer DS et al.: DDAVP-induced release of von Willebrand factor from endothelial cells in vitro: the effect of plasma and blood cells. Biochem Biophys Acta 1990;1052:63-70.
8. Macia RA, Silver AC, Gabel RA et al.: Hypotension induced by vasopressin antagonists in rats: role of mast cell degranulation. Toxicol Appl Pharmacol 1990;102: 117-127.
9. Johns RA: Desmopressin is a potent vasorelaxant of aorta and pulmonary artery isolated from rabbit and rat. Anesthesiology 1990;72:858-864.
10. Murphy DJ, Joran ME: Respiratory and cardiovascular changes associated with toxic doses of a peptide antagonist of vasopressin in the rat. Fundam Appl Toxicol 1992;18:307-313.
11. Mannucci PM, Ruggeri ZM, Paretti FI, Capitanio A: 1-Deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand's disease. Lancet 1977;1:869-872.
12. Niessner H, Korninger C: 1-Deamino-8-D-arginine vasopressin: an alternative in the management of mild haemophilia A and von Willebrand' disease. Wien Klin Wochenschr 1983;95:753-757.
13. Mannucci PM, Vicente V, Alberca I, Sacchi E, et al.: Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses. Thromb Haemost 1987;58: 1037-1039.
14. Köhler M, Harris A: Pharmacokinetics and haematological effects of desmopressin. Eur J Clin Pharmacol 1988; 35:281-285.
15. Lethagen S, Harris AS, Sjörin E, Nilsson IM: Intranasal and intravenous administration of desmopressin: Effect on FVIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost 1987;58:1033-1036.
16. Garcia VV, Coppola R, Mannucci PM: The role of the spleen in regulating the plasma levels of factor VIII-von Willebrand's factor after desmopressin. Blood 1982;60: 1402-1406.